Home›Trial›NCT07015190
🔬NCT07015190Phase 3RECRUITING

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Study Summary

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

Conditions
Uveal Melanoma
Interventions / Drugs
DarovasertibPrimary Local Therapy
View on ClinicalTrials.gov ↗
Sponsor
IDYA
IDEAYA Biosciences
Precision Oncology
D38/100
Study Details
Enrollment520 participants
Primary Completion—
Lead SponsorIDEAYA Biosciences
Data Retrieved2026-04-11 04:16:36.812107+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.